{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:09:45Z","timestamp":1789852185681,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/nrclinonc.2012.83","type":"journal-article","created":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T07:24:21Z","timestamp":1335857061000},"page":"310-311","source":"Crossref","is-referenced-by-count":9,"title":["Gemtuzumab ozogamicin in acute myeloid leukaemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,1]]},"reference":[{"key":"BFnrclinonc201283_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cncr.21543","volume":"107","author":"W Kern","year":"2006","unstructured":"Kern, W. & Estey, E. H. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 107, 116\u2013124 (2006).","journal-title":"Cancer"},{"key":"BFnrclinonc201283_CR2","doi-asserted-by":"crossref","first-page":"a257","DOI":"10.1182\/blood.V118.21.257.257","volume":"118","author":"R Willemze","year":"2011","unstructured":"Willemze, R. et al. High dose (HD-AraC) vs. standard dose cytosine arabinoside (SD-AraC) during induction and IL-2 vs. observation after consolidation\/autologous stem cell transplantation in patients with acute myelogenous leukemia (AML): Final report of the AML-12 trial of EORTC and GIMEMA Leukemia groups on the value of high dose AraC [abstract]. Blood 118, a257 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc201283_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg, B. et al. Cytarabine dose for acute myeloid leukemia. N. Engl. J. Med. 364, 1027\u20131036 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201283_CR4","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield, C. D. et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58, 4173\u20134179 (1998).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201283_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez, H. F. et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl. J. Med. 361, 1249\u20131259 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201283_CR6","doi-asserted-by":"publisher","unstructured":"Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet http:\/\/dx.doi.org\/10.1016\/S0140\u20136736(12)60485\u20131 .","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"BFnrclinonc201283_CR7","doi-asserted-by":"crossref","first-page":"a790","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"S Petersdorf","year":"2009","unstructured":"Petersdorf, S. et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract]. Blood 114, a790 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201283_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett, A. K. et al. Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J. Clin. Oncol. 29, 369\u2013377 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201283_CR9","doi-asserted-by":"crossref","first-page":"a79","DOI":"10.1182\/blood.V118.21.79.79","volume":"118","author":"J Delaunay","year":"2011","unstructured":"Delaunay, J. et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract]. Blood 118, a79 (2011).","journal-title":"Blood"},{"key":"BFnrclinonc201283_CR10","doi-asserted-by":"crossref","first-page":"a582","DOI":"10.1182\/blood.V118.21.582.582","volume":"118","author":"AK Burnett","year":"2011","unstructured":"Burnett, A. K. et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial [abstract]. Blood 118, a582 (2011).","journal-title":"Blood"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2012.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2012.83","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2012.83.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:21:41Z","timestamp":1684466501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2012.83"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,1]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFnrclinonc201283"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2012.83","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,1]]}}}